News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News TOHO and Haneda Airport Team Up for Godzilla Global Project Launch News Blockpass & BAS Secure Binance’s BNB Chain with Reusable, Verifiable Credentials News Japan IT Week Autumn 2025: NIPA Expands South Korea’s Presence in Japan’s AI and Deep Tech Ecosystem News Trio AI and HTHK Sign MOU to Expand 5G-Powered Smart Robotics in Property Management, Construction, and Public Services Organizations, Advancing Hong Kong’s Smart City Vision News Shoucheng x Wisson: World’s First ‘Robotic Auto-Charging’ Pilot Ends News Deveron Provides Update on Financials